Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Down more than 40% this year, DexCom's stock has been in a tailspin. But while it might seem like a troubling time to own the stock, here are three reasons I would consider buying it. I've always ...

Down more than 40% this year, DexCom's stock has been in a tailspin. But while it might seem like a troubling time to own the stock, here are three reasons I would consider buying it. 1.

I managed to lose seven pounds. SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced ...

New York, New York--(Newsfile Corp. - September 14, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...

DexCom is one of the leaders in an industry with ... meters that can only tell a person's sugar level at a particular time. CGMs do so automatically and continuously throughout the day.

Medical device specialist DexCom (NASDAQ: DXCM ... meters that can only tell a person's sugar level at a particular time. CGMs do so automatically and continuously throughout the day.

Patients could buy a pack of two sensors at a one-time price of $99 or opt for a subscription to get a monthly delivery for $89, Dexcom said. Abbott had said it plans to launch Lingo in the U.S ...

That’s because on the underside of my left arm is a Dexcom Stelo continuous glucose ... Unlike Type 1, Type 2 diabetes develops over time as the body becomes more insulin-resistant.

DexCom’s CGM system is superior to traditional fi nger-stick tests because it provides users with continuous data (including glucose trends and time spent in hyper or hypoglycemia) versus a ...

7 Studies show the use of Dexcom glucose biosensing by people with Type 2 diabetes is associated with clinically meaningful improvement in time in range, A1c and quality of life.8-11 Stelo is now ...